Transcept Pharmaceuticals Revenue Growth: -80.00%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TSPT Revenue Growth Rankings
| Overall | 0th percentile | 4397 of 4424 |
| Sector | 2nd percentile | 454 of 464 in Healthcare |
| Industry | 4th percentile | 121 of 127 in Biotechnology |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these TSPT related companies
TSPT News
JMP Securities Starts Transcept Pharmaceuticals (TSPT) at Market Outperform
Feb 10, 8:22AM Street Insider
Feb 10, 8:22AM Street Insider
I can't sleep war!!...now $SOMX downgraded PT $0.75, after $TSPT upgrade. Stock price alone speaks here
about 2 days ago by highgrowthfinancial
about 2 days ago by highgrowthfinancial
here we go, an old favorite winning over more analyst. $TSPT started coverage with $15 @ JMP
about 2 days ago by highgrowthfinancial
about 2 days ago by highgrowthfinancial
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
Feb 07, 8:05AM PR Newswire
Feb 07, 8:05AM PR Newswire
@EXPstocktrader any thoughts on purdue $TSPT partnership....PT?
about 19 days ago by highgrowthfinancial
about 19 days ago by highgrowthfinancial
$TSPT price target about 3 months ago was $22.50 before FDA approval
about 52 days ago by gauntlet21
about 52 days ago by gauntlet21
$TSPT is surging on high volume; FDA approved drug to sell in 2Q; received money from Purdue; Purdue to invest 100M for launch
about 52 days ago by gauntlet21
about 52 days ago by gauntlet21
Transcept Pharmaceuticals (TSPT) Earns $10 Million in Milestone Payments from Purdue
Dec 21, 4:07PM Street Insider
Dec 21, 4:07PM Street Insider
$TSPT now flat for 3 months @ $6.95. looks like it could finish small HnS pattern soon. I will keep on list but sold out 4 now
about 55 days ago by highgrowthfinancial
about 55 days ago by highgrowthfinancial
Transcept Pharmaceuticals shares have limited downside, says Lazard Capital
Dec 12, 8:10AM theflyonthewall.com
Dec 12, 8:10AM theflyonthewall.com
$tspt fillin gaps here!! looks strong. insiders don't sell that many shares everyday forever.
about 65 days ago by highgrowthfinancial
about 65 days ago by highgrowthfinancial
Transcept Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
Dec 08, 4:05PM PR Newswire
Dec 08, 4:05PM PR Newswire
$TSPT gonna take some time from $2.58 low. but should fill gap over time.
about 68 days ago by highgrowthfinancial
about 68 days ago by highgrowthfinancial
Transcept Pharmaceuticals gaps up, resistance at $9.37, November's pivot high
Dec 01, 8:18AM FlyOnTheWall
Dec 01, 8:18AM FlyOnTheWall
Transcept (TSPT) Announces Purdue Exercised Option to Commercialize Intermezzo in the US; Shares Rallying
Dec 01, 7:58AM Street Insider
Dec 01, 7:58AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TSPT | 8.28 | 0.13 | 1.60% | 111.95M |
| OMEX | 3.36 | -0.06 | -1.75% | 244.57M |
| TWER | 2.71 | -0.09 | -3.05% | 144.04M |
| EBAY | 33.02 | -0.23 | -0.71% | 42.63B |
| NCTY | 7.44 | 0.06 | 0.81% | 173.13M |
| MSFT | 30.50 | -0.28 | -0.89% | 256.53B |
| WBMD | 27.09 | -0.51 | -1.85% | 1.59B |
| AMGN | 67.36 | 0.52 | 0.78% | 59.04B |
| ALSK | 2.81 | -0.02 | -0.71% | 127.01M |
| NWSA | 19.18 | -0.04 | -0.18% | 33.02B |
